Get the Stockscreener App
1.10
2.22%
-0.025
Opko Health Inc stock is traded at $1.10, with a volume of 1.96M.
It is down -2.22% in the last 24 hours and down -2.65% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.125
Open:
$1.13
24h Volume:
1.96M
Relative Volume:
0.76
Market Cap:
$830.60M
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-4.0175
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
-10.57%
1M Performance:
-2.65%
6M Performance:
-19.12%
1Y Performance:
-18.52%
1-Day Range:
$1.10
$1.14
1-Week Range:
$0.9769
$1.22
52-Week Range:
$0.9769
$1.60
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.10 | 830.60M | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
469.21 | 174.37B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.15 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.46 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.52 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
307.12 | 30.15B | 3.17B | 642.63M | 516.49M | 10.77 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
Here's why you should hold OPK stock in your portfolio for now - MSN
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[DEF 14A] OPKO HEALTH, INC. Definitive Proxy Statement - Stock Titan
MSN Money - MSN
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
Kidney drug RAYALDEE targets China as OPKO takes 15% Nicoya stake - Stock Titan
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
BioReference® Launches BioReference Direct™, Expanding - GlobeNewswire
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - Yahoo Finance
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada
OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat
OPKO Health Q1 Earnings Call Highlights - Yahoo Finance
OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip By Investing.com - Investing.com South Africa
Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip - Investing.com Nigeria
Earnings Flash (OPK) OPKO Health Posts Q1 Loss of $0.07 per Share, vs. FactSet Est of $0.07 Loss - marketscreener.com
OPKO Health Inc (NASDAQ:OPK) Misses Q1 Revenue Estimates, Shares Slide After Hours - ChartMill
OPKO Health: Q1 Earnings Snapshot - Barchart.com
OPKO Health (NASDAQ:OPK) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings Flash (OPK) OPKO Health, Inc. Reports Q1 Revenue $124.2M, vs. FactSet Est of $130.5M - marketscreener.com
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results - The Manila Times
(OPK) OPKO Health, Inc. Expects Q2 Revenue Range $127.0M$132.0M - marketscreener.com
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
OPKO Health (NASDAQ: OPK) Q1 2026 revenue falls as net loss narrows - Stock Titan
OPKO Health (NASDAQ: OPK) Q1 2026 revenue falls as losses narrow and guidance held - Stock Titan
OPKO Health Provides Revenue Guidance for the Second Quarter Ending June 30, 2026; Reaffirms Revenue Guidance for the Full Year Ending December 31, 2026 - marketscreener.com
How The OPKO Health (OPK) Narrative Is Shifting After Mixed Results And A Lower Price Target - Yahoo Finance
Here's Why You Should Hold OPK Stock in Your Portfolio for Now - TradingView
OPK (OPKO Health) beats Q4 2025 EPS expectations but shares drop 2.02% amid 14.9% year-over-year revenue decline.Hedge Fund Inspired Picks - Xã Châu Thành
A four-target antibody enters human testing in B-cell lymphoma - Stock Titan
OPKO Health (OPK) to Release Earnings on Wednesday - MarketBeat
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas - Yahoo Finance
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 - OPKO Health, Inc.
OPKO to give 2026 guidance and business update after April 28 results - Stock Titan
OPKO Health (OPK) Stock: Market Opportunity? (-2.42%) 2026-04-20Viral Trade Signals - Cổng thông tin điện tử Tỉnh Sơn La
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
0.37%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):